4-Methoxy-butyric acid ethyl ester | 69243-09-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4-Methoxy-butyric acid ethyl ester
• 英文别名: Ethyl 4-methoxybutanoate
• CAS: 69243-09-0
• 化学式: C₇H₁₄O₃
• 分子量: 146.186
• InChiKey: UVDARLMCNXCOGS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  三氟乙酸乙酯 、 4-Methoxy-butyric acid ethyl ester 在 sodium hydride 作用下， 生成 4,4,4-trifluoro-2-(2-methoxy-ethyl)-3-oxo-butyric acid ethyl ester
  参考文献：
  名称：

  尝试将致命合成应用于化学治疗剂的设计。氟化的5个β-（羟乙基）-4-甲基噻唑。

  摘要：

  DOI：

  10.1021/jm00189a017
• 作为产物：
  描述：

  4-甲氧基丁酸 、 乙醇 以85%的产率得到
  参考文献：
  名称：

  ARCHER S.; PERIANAYAGAM C., J. MED. CHEM., 1979, 22, NO 3 306-309

  摘要：

  DOI：

文献信息

• NOVEL URSOLIC ACID DERIVATIVE AND METHOD FOR PREPARING SAME
  申请人：Nexoligo Co., Ltd.

  公开号：US20150218206A1

  公开（公告）日：2015-08-06

  The present invention relates to a novel ursolic acid derivative as an ursolic acid prodrug form, and to a method for preparing same, wherein the novel ursolic acid derivative as an ursolic acid prodrug can have excellent pharmacokinetic characteristics such as stability and oral absorptivity and exhibit excellent pharmaceutical activities by being converted into an ursolic acid in vivo, and. The ursolic acid derivative can be in an ester form in which C28 carboxylic acid in the ursolic acid is combined with a prodrug of a certain pharmaceutical compound.

  本发明涉及一种新颖的熊果酸衍生物作为熊果酸前药形式，以及制备该衍生物的方法，其中作为熊果酸前药的新颖熊果酸衍生物可以具有优秀的药代动力学特性，如稳定性和口服吸收性，并通过在体内转化为熊果酸而展现出优秀的药用活性。该熊果酸衍生物可以以酯形式存在，其中熊果酸中的C28羧酸与某种药物化合物的前药结合。
• CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR
  申请人：Luly Jay R.

  公开号：US20090281081A1

  公开（公告）日：2009-11-12

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

  本发明涉及新化合物以及一种治疗与异常白细胞招募和/或激活相关的疾病的方法。该方法包括向需要治疗的受体内给予一种有效量的化合物，该化合物表示为：或其生理上可接受的盐。
• NOVEL CASE OF RENIN INHIBITORS
  申请人：Wu Tom Yao-Hsiang

  公开号：US20100120859A1

  公开（公告）日：2010-05-13

  The present invention relates to piperidine-based renin inhibitor compounds having carboxylate or carboxylic acid terminal groups, and their use in treating cardiovascular events and renal insufficiency.

  本发明涉及基于哌啶的肾素抑制剂化合物，其具有羧酸盐或羧酸末端基团，并且它们在治疗心血管事件和肾功能不全方面的使用。
• CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
  申请人：Luly Jay R.

  公开号：US20120046311A1

  公开（公告）日：2012-02-23

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

  本发明涉及新化合物和治疗与异常白细胞招募和/或激活相关的疾病的方法。该方法包括向需要治疗的受试者施用有效量的以下化合物或其生理上可接受的盐：（图片无法显示，请见谅）
• N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE
  申请人：Suetsugu Satoshi

  公开号：US20120122773A1

  公开（公告）日：2012-05-17

  The present invention provides a compound of formula (I): wherein R 1a is optionally substituted C 1-6 alkyl, etc.; R 1m is hydrogen atom, etc.; G 1 , G 2 , G 3 and G 4 are (i), etc. ((i) G 1 is —N(R 1b )—, G 2 is —CO—, G 3 is —C(R 1c )(R 1d )—, and G 4 is oxygen, etc.); R 1b is optionally substituted C 1-6 alkyl, etc.; R 1c and R 1d are each independently optionally substituted C 1-6 alkyl, etc.; R 2 is optionally substituted C 1-6 alkyl, etc.; R 3a , R 3b , R 3c and R 3d are each independently a group: -A-B (A is a single bond, etc., B is hydrogen atom, etc.), etc.; n is 1, etc.; R 5 is C 1-4 alkoxycarbonyl, etc., or a pharmaceutically acceptable salt thereof, which is useful as a renin inhibitor.

  本发明提供了一种化合物，其化学式为(I)：其中R1a是可选取代的C1-6烷基等；R1m是氢原子等；G1，G2，G3和G4是(i)等，((i) G1是—N(R1b)—，G2是—CO—，G3是—C(R1c)(R1d)—，G4是氧原子等)；R1b是可选取代的C1-6烷基等；R1c和R1d分别独立地是可选取代的C1-6烷基等；R2是可选取代的C1-6烷基等；R3a、R3b、R3c和R3d分别独立地是一种基团：-A-B（其中A是单键等，B是氢原子等）等；n是1等；R5是C1-4烷氧羰基等，或其药学上可接受的盐，其作为一种肾素抑制剂是有用的。